[1] Siedner MJ, Tumarkin E, Bogoch II. HIV post-exposure prophylaxis (PEP). BMJ 2018;363:k4928. https://doi.org/10.1136/bmj.k4928.
[2] Krakower DS, Jain S, Mayer KH. Antiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxis. Curr HIV/AIDS Rep 2015;12(1):127 − 38. https://doi.org/10.1007/s11904-014-0253-5.
[3] Smith DK, Grohskopf LA, Black RJ, Auerbach JD, Veronese F, Struble KA, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep 2005;54(Rr-2):1-20. https://pubmed.ncbi.nlm.nih.gov/15660015/.
[4] Maisano M, Tran D, Macdonald V, Baggaley RC, Ford N, Johnson CC, et al. A global review of national guidelines of post-exposure prophylaxis for the prevention of HIV. J Int AIDS Soc 2025;28(1):e26333. https://doi.org/10.1002/jia2.26333.
[5] Wang XF, Xu J, Wu ZY. A pilot program of pre-exposure and post-exposure prophylaxis promotion among men who have sex with men — 7 study sites, China, 2018-2019. China CDC Wkly 2020;2(48):917 − 9. https://doi.org/10.46234/ccdcw2020.250.
[6] National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention. Technical Guidelines for Post-Exposure Prophylaxis of HIV. 2020. https://ncaids.chinacdc.cn/tzgg_10268/202011/W020201116802422550750.pdf. [2022-9-10]. (In Chinese).
[7] Xu J, Zhang G, Dong W. The promotion and application of pre- and post-exposure prophylaxis measures for HIV in China. Chin J AIDS STD 2023;29(11):1167-71. http://dx.doi.org/10.13419/j.cnki.aids.2023.11.01. (In Chinese).
[8] Ford N, Irvine C, Shubber Z, Baggaley R, Beanland R, Vitoria M, et al. Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysis. Aids 2014;28(18):2721 − 7. https://doi.org/10.1097/QAD.0000000000000505.
[9] Shan D, Xue H, Yu F, Zan XK, Liu H, Liu JY, et al. Understanding the uptake and outcomes of non-occupational postexposure prophylaxis use through an online medical platform in China: web-based cross-sectional study. J Med Internet Res 2023;25(1):e42729. https://doi.org/10.2196/42729.
[10] Wu YF, Zhu QY, Zhou YJ, Liang SJ, Li RJ, Liang NX, et al. Implementation of HIV non-occupational post-exposure prophylaxis for men who have sex with men in 2 cities of southwestern China. Medicine (Baltimore) 2021;100(43):e27563. https://doi.org/10.1097/MD.0000000000027563.
[11] Fan CX, Yin ZH, Li CY, Dai YF, Zhao HP, Marley G, et al. Impact of peer referral on pre-exposure prophylaxis adherence and persistence among men who have sex with men: a cohort study in China. AIDS Behav. 2025;29(6):1831 − 40. https://doi.org/10.1007/s10461-025-04651-9.
[12] Cui TY, Li TY, Gong LY, Wang KX, Luo QQ. Preliminary evaluation of a gamified smartphone intervention (O2O-PEP) for enhancing HIV post-exposure prophylaxis uptake in men who have sex with men: pilot feasibility study. BMC Public Health 2025;25(1):1539. https://doi.org/10.1186/s12889-025-22818-w.
[13] Sha YJ, Li CY, Xiong Y, Hazra A, Lio J, Jiang I, et al. Co-creation using crowdsourcing to promote PrEP adherence in China: study protocol for a stepped-wedge randomized controlled trial. BMC Public Health 2022;22(1):1697. https://doi.org/10.1186/s12889-022-14117-5.
[14] Liu A, Xin RL, Zhang HW, Dai LL, Wu RE, Wang X, et al. An open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to human immunodeficiency virus-1. Chin Med J (Engl) 2022;135(22):2725 − 9. https://doi.org/10.1097/CM9.0000000000002494.
[15] Malinverni S, Gennotte AF, Schuster M, De Wit S, Mols P, Libois A. Adherence to HIV post-exposure prophylaxis: a multivariate regression analysis of a 5 years prospective cohort. J Infect 2018;76(1):78 − 85. https://doi.org/10.1016/j.jinf.2017.10.008.